VectorY therapeutics licenses Shape AAV5 capsid for neurodegenerative treatments

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

VectorY Therapeutics and Shape Therapeutics have entered an option and license agreement to advance vectorized antibody therapies for neurodegenerative diseases, according to the company. The deal grants VectorY exclusive rights to evaluate Shape’s SHP-DB1, a deep-brain-penetrating AAV5-derived capsid, for vectorized antibodies targeting three therapeutic areas. Upon successful evaluation, VectorY may obtain an exclusive license for commercialization.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE